The World Health Organization advised on Tuesday against the general use of ‘ivermectin’, an orally administered drug used to treat parasitic infections for the treatment of COVID-19 patients.
The chief scientist of the global health organization, Dr. “Safety and efficacy are important when using any drug for a new indication. WHO recommends not using ‘ivermectin’ for COVID-19 outside of clinical trials,” tweeted Soumya Swaminathan.
A similar warning, Dr. It was also published by German health and life sciences giant Merck, which Swaminathan added to his tweet. Merck said scientists continue to “carefully examine the findings of all existing and emerging ‘ivermectin’ studies for the treatment of COVID-19.”
“ … to date, our analysis has determined: There is no scientific basis for a potential therapeutic effect against COVID-19 from preclinical studies; No significant evidence for clinical activity or efficacy in patients with COVID-19 disease and; about the lack of security data, ”he said.
– Soumya Swaminathan (@doctorsoumya) 10 May 2021
This is the second WHO warning against “ivermectin” in the past two months.
In March, he said there was “very low certainty evidence” of the drug’s effect on mortality or hospitalization.
“We currently do not have convincing evidence of a mechanism of action for ‘ivermectin’ in COVID-19, and any observed clinical benefit cannot be explained,” said WHO.
Dr Swaminathan’s tweet came a day after Goa approved ‘ivermectin’ as a preventive treatment for all adults against the SARS-CoV2 virus that causes COVID-19 disease.
Goa Health Minister Vishwajit P Rane said the state’s drug green illumination occurred after expert panels from the UK, Italy, Spain and Japan found a statistically significant reduction in mortality, recovery time, and viral clearance in COVID-19 patients. Treated with ‘ivermectin’.
Mr. Rane said that the treatment – 12 mg for five days – would apply to anyone over the age of 18.
Patients will be treated with 12 mg of Ivermectin over a period of 5 days. Expert panels from the UK, Italy, Spain, and Japan found a large, statistically significant reduction in mortality, recovery time, and viral clearance in Covid-19 patients treated with Ivermectin. (2/4)
– VishwajitRane (@visrane) 10 May 2021
Last month, the Union Ministry of Health published revised guidelines for home isolation of asymptomatic Covid cases, stating the use of ‘ivermectin’ to control fever.
Given the growing controversy over the efficacy of ‘ivermectin’, which is approved – in certain doses – for infections caused by some parasitic worms, the WHO chief scientist’s tweet today is significant.
At this stage, it is not considered an antiviral drug; This is something the United States Food and Drug Administration emphasized by saying that “Ivermectin is not approved for the treatment of COVID-19.”
However, there is some research suggesting the opposite.
A review of available data published in the May-June issue of the American Journal of Therapeutics – could help end the ‘ivermectin’ epidemic.
“We did the most comprehensive review of available data on ivermectin,” said Pierre Kory, President and Chief Medical Officer of the Front Line COVID-19 Critical Care Alliance (FLCCC), a group of medical and scientific experts who led the study. .
The authors claimed a large and statistically significant reduction in mortality, recovery time, and viral clearance in COVID-19 patients treated with ‘ivermectin’.
‘Ivermectin’ is one of a number of antiviral or other medications researched and offered for COVID-19 treatment options. Others include Remdesivir, which is in great demand in India, and the malaria drug hydroxychloroquine, whose large quantities were exported by India last year.
The World Health Organization still does not approve of hydroxychloroquine, and last month the center said remdesivir is not a life-saving drug and that the use of “unnecessary or unreasonable” in Covid patients is unethical.
However, Remdesivir is routinely recommended for treatment in India.
While many countries are battling devastating waves of infections, drugs used to treat or mitigate the impact of COVID-19 continue to make headlines in India and around the world.
This morning, India, the current epicenter of the outbreak, reported more than 3.2 million new cases and 3,876 deaths in the past 24 hours. The number of active cases is currently over 37.15 lakh.
With input from AFP, PTI